Search (News)

Update On FDA Priority Review Of LEQEMBI® IQLIKTM (Lecanemab-Irmb) Subcutaneous Injection As A Starting Dose For Early Alzheimer's Disease

english top health

(MENAFN - PR Newswire) TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB ) today announced that the U.S. Food and Drug Administration (FDA) has ...
2026-05-08 03:07:46